Business Context and Reporting Period
Company: StemCells, Inc. (Note: Request metadata listed "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Reporting Period: Fiscal Year Ended December 31, 2003
Business Overview: The Company is a biopharmaceutical firm focused on developing stem and progenitor cell therapies for neurodegenerative diseases (e.g., Batten's, Parkinson's, Alzheimer's), spinal cord injuries, liver failure, and diabetes. The Company utilizes tissue-derived cells (fetal or adult) and does not use embryonic stem cells or engage in human cloning. Operations are centered in Palo Alto, California, with legacy facilities in Rhode Island being wound down.
Key Financial Metrics
| Metric | 2003 | 2002 | 2001 |
|---|---|---|---|
| Total Revenue | $273,430 | $415,377 | $805,231 |
| Net Loss (Applicable to Common Shareholders) | $(14,425,160) | $(13,275,986) | $(5,567,414) |
| Loss Per Share (Basic & Diluted) | $(0.45) | $(0.53) | $(0.25) |
| Cash and Cash Equivalents (Year End) | $13,081,703 | $4,236,367 | $13,697,195 |
| Total Assets | $19,786,414 | $11,328,822 | $20,803,000 (Restated) |
| Long-Term Debt & Capital Leases | $1,849,583 | $2,086,667 | $2,316,000 (Restated) |
| Stockholders' Equity | $10,963,558 | $1,933,369 | $12,632,807 (Restated) |
Note: Financial data for 2001 and 2002 has been restated to reflect changes in accounting for wind-down expenses and lease incentives.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 34% from $415,377 in 2002 to $273,430 in 2003. This was primarily due to the completion of a $150,000 SBIR grant in 2002 and only partial drawdown of a $225,000 NIDDKD grant in 2003. Licensing revenue was minimal at $18,307.
- Operating Expenses: Research and development expenses decreased 17% to $6.14 million, driven by a cost reduction program initiated in late 2002 (workforce reduction, reduced supplies/services). General and administrative expenses remained relatively flat at $3.39 million.
- Wind-Down Accruals: The Company significantly increased its reserve for the wind-down of its former Rhode Island facilities. The reserve was revised to $2,676,000 at year-end 2003, compared to $775,000 at year-end 2002, reflecting uncertainty in subleasing the property.
- Liquidity Improvement: Cash and cash equivalents increased significantly from $4.2 million in 2002 to $13.1 million in 2003, primarily due to equity financings totaling approximately $16.1 million (net of issuance costs) and warrant exercises.
Guidance, Outlook, and Risks
- Going Concern: The auditors (Grant Thornton LLP) have issued a report raising substantial doubt about the Company's ability to continue as a going concern due to significant operating losses and negative cash flows since inception. Management plans to fund operations through existing cash, equity/debt offerings, and grants.
- Capital Resources: Management states existing capital resources are sufficient to fund operations through the end of 2004. Additional financing will be required to sustain product development and clinical trials.
- Development Pipeline:
- Neural Program: Preclinical stage. The Company plans to file an Investigational New Drug (IND) application for Batten's disease in Q1 2005. Preclinical studies for spinal cord injury and stroke have shown proof of principle in animal models.
- Liver Program: Research stage. Identified candidate human liver engrafting cells (hLEC) and demonstrated engraftment in mouse models.
- Pancreas Program: Research stage, primarily pursued through external collaborators.
- Risks:
- Failure to secure additional financing or corporate partnerships.
- Delays or adverse results in preclinical and clinical testing.
- Intellectual property challenges, including opposition to two European patents.
- Continued costs associated with the Rhode Island facility wind-down.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $13.1 million cash balance to fund operations through the end of 2004 and the timeline for the planned Q1 2005 IND filing.
- Rhode Island Liability: Confirm the accuracy of the $2.676 million wind-down reserve and the Company's progress in subleasing or selling the Rhode Island facilities to mitigate ongoing lease obligations.
- Financing Terms: Review the terms of the recent financing agreements with Riverview Group, L.L.C., including warrant exercise prices and potential dilution.
- Patent Status: Monitor the outcome of the opposition proceedings against the Company's two issued European patents.
- Grant Revenue: Assess the sustainability of revenue from government grants (NINDS, NIDDKD) given the Company's statement that it does not intend to draw further funds from certain grants.